{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:43:33Z","timestamp":1787579013461,"version":"build-2736575974"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2\n                    <jats:italic>in vitro<\/jats:italic>\n                    and in SARS-CoV-2-infected animal models but also for (ii) clearance of virus-infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule, which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor-modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1204543","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:22:30Z","timestamp":1686615750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexandra","family":"Kegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Drewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Daglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Rodrigues Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mitwasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Neuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla Elizabeth","family":"Gonz\u00e1lez Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Baraban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Ziehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Nieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Moreira-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"K\u00fchne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Felix","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Laube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domokos","family":"M\u00e1th\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"P\u00e1lyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polett","family":"Hajdrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Forg\u00e1ch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriszti\u00e1n","family":"Szigeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"B1","unstructured":"WHO COVID-19 dashboard2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by south African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02212-y","article-title":"Estimating the transmission dynamics of SARS-CoV-2 omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November\u2013December 2022","volume":"29","author":"Leung","year":"2023","journal-title":"Nat Med"},{"key":"B7","first-page":"79","volume-title":"The COVID-19 pandemic in 2023: far from over","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00685-21","article-title":"Characterization of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants","volume":"95","author":"Ferrari","year":"2021","journal-title":"J Virology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","article-title":"Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2","volume":"12","author":"Higuchi","year":"2021","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7737","article-title":"An engineered ACE2 decoy neutralizes the SARS-CoV-2 omicron variant and confers protection against infection in vivo","volume":"14","author":"Ikemura","year":"2022","journal-title":"Sci Trans Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105271","DOI":"10.1016\/j.antiviral.2022.105271","article-title":"ACE2-fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern","volume":"199","author":"Tsai","year":"2022","journal-title":"Antiviral Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-021-00965-6","article-title":"Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants","volume":"18","author":"Zhang","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41421-021-00302-0","article-title":"Potent prophylactic and therapeutic efficacy of recombinant human ACE2-fc against SARS-CoV-2 infection in vivo","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684014","article-title":"Potent SARS-CoV-2-Specific T cell immunity and low anaphylatoxin levels correlate with mild disease progression in COVID-19 patients","volume":"12","author":"Lafon","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16927","article-title":"ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2\u2013specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report","volume":"22","author":"Martits-Chalangari","year":"2022","journal-title":"Am J Transplantation."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010339","article-title":"SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants","volume":"18","author":"Panikkar","year":"2022","journal-title":"PloS Pathogens."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2024202118","article-title":"The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg6461","article-title":"SARS-CoV-2 mutations in MHC-i-restricted epitopes evade CD8+ T cell responses","volume":"6","author":"Agerer","year":"2021","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00018-022-04592-9","article-title":"Induction of pulmonary HLA-G expression by SARS-CoV-2 infection","volume":"79","author":"Seliger","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106267","article-title":"Syncytia formation by SARS-CoV-2-infected cells","volume":"39","author":"Buchrieser","year":"2020","journal-title":"EMBO J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/antib1020172","article-title":"Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs","volume":"1","author":"Stamova","year":"2012","journal-title":"Antibodies"},{"key":"B28","doi-asserted-by":"publisher","first-page":"956304","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J Biomedicine Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol Letters."},{"key":"B33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/leu.2013.243","article-title":"Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system","volume":"28","author":"Arndt","year":"2014","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood.V124.21.3494.3494","article-title":"Flexible antigen-specific redirection of human regulatory T cells Via a novel universal chimeric antigen receptor system","volume":"124","author":"Koristka","year":"2014","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J Autoimmunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02399-5","article-title":"Conventional CARs versus modular CARs","volume":"68","author":"Feldmann","year":"2019","journal-title":"Cancer Immunology Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","article-title":"\u201cUniCAR\u201d-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells","volume":"10","author":"Mitwasi","year":"2020","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03374-x","article-title":"Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers","author":"Pfeifer Serrahima","year":"2023","journal-title":"Cancer Immunology Immunotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1287246","DOI":"10.1080\/2162402X.2017.1287246","article-title":"A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform","volume":"6","author":"Albert","year":"2017","journal-title":"OncoImmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22850","article-title":"Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system","volume":"74","author":"Arndt","year":"2014","journal-title":"Prostate."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22851","article-title":"Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells","volume":"74","author":"Arndt","year":"2014","journal-title":"Prostate."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23556","article-title":"Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells","volume":"9","author":"Bachmann","year":"2017","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR\u201d","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1621676","article-title":"T Cells engrafted with a UniCAR 28\/z outperform UniCAR BB\/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression","volume":"8","author":"Kegler","year":"2019","journal-title":"OncoImmunology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-018-0113-4","article-title":"Development of a novel target module redirecting UniCAR T cells to sialyl tn-expressing tumor cells","volume":"8","author":"Loureiro","year":"2018","journal-title":"Blood Cancer J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.3390\/ijms23094920","article-title":"Targeting CD10 on b-cell leukemia using the universal CAR T-cell platform (UniCAR)","volume":"23","author":"Mitwasi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21017","article-title":"Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells","volume":"8","author":"Mitwasi","year":"2017","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/10.13.4071","article-title":"The nucleotide sequence of a human immnnoglobulin c\u03b3l gene","volume":"10","author":"Ellison","year":"1982","journal-title":"Nucleic Acids Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0014-4827(89)90038-4","article-title":"Identification of la ribonucleoproteins as a component of interchromatin granules","volume":"185","author":"Carmo-Fonseca","year":"1989","journal-title":"Exp Cell Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.937676","article-title":"Editorial: world health organization (WHO) variants of concern lineages under monitoring (VOC-LUM) in response to the global spread of lineages and sublineages of omicron, or B.1.1.529, SARS-CoV-2","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65962","article-title":"SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation","volume":"10","author":"Sanders","year":"2021","journal-title":"eLife"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216109","article-title":"An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin Pharmacokinetics"},{"key":"B62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12024","article-title":"An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension","volume":"12","author":"Simon","year":"2022","journal-title":"Pulmonary Circulation."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/vaccines10050743","article-title":"Increased receptor affinity and reduced recognition by specific antibodies contribute to immune escape of SARS-CoV-2 variant omicron","volume":"10","author":"Vogt","year":"2022","journal-title":"Vaccines"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Advances."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for b-cell malignancies: results of a multicenter study on behalf of the European society for blood and marrow transplantation (EBMT) infectious diseases working party and the European hematology association (EHA) lymphoma group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplantation."},{"key":"B73","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/pros.21315","article-title":"Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats","volume":"71","author":"Feldmann","year":"2011","journal-title":"Prostate."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20608","article-title":"Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells","volume":"67","author":"Morgenroth","year":"2007","journal-title":"Prostate."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.6.2059","article-title":"One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La\/SS-b from a cDNA library of a patient with primary sj\u00f6grens\u2019 syndrome","volume":"180","author":"Tr\u00f6ster","year":"1994","journal-title":"J Exp Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00558.x","article-title":"The value of synthetic linear epitope analogues of La\/SSB for the detection of autoantibodies to La\/SSB; specificity, sensitivity and comparison of methods","volume":"112","author":"Yiannaki","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.01.002","article-title":"Retargeting of regulatory T cells to surface-inducible autoantigen La\/SS-b","volume":"42","author":"Koristka","year":"2013","journal-title":"J Autoimmunity."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/ijms22031198","article-title":"T Cell mediated conversion of a non-Anti-La reactive b cell to an autoreactive anti-la b cell by somatic hypermutation","volume":"22","author":"Bachmann","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016315","article-title":"A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs)","volume":"6","author":"Bippes","year":"2011","journal-title":"PloS One"},{"key":"B81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/foods11050694","article-title":"In vitro determination of inhibitory effects of humic substances complexing zn and Se on SARS-CoV-2 virus replication","volume":"11","author":"Hajdrik","year":"2022","journal-title":"Foods"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im0104s27","article-title":"Anesthesia","volume":"27","author":"Donovan","year":"1998","journal-title":"Curr Protoc Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"OncoImmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1204543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:22:33Z","timestamp":1686615753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1204543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2023.1204543"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1204543","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"1204543"}}